Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Metagenomi Therapeutics (MGX) Gains from Sales and Divestitures (2024 - 2025)

Metagenomi (MGX) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $308058.0 as the latest value for Q4 2025.

Quarterly Gains from Sales and Divestitures fell 38.28% to $308058.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $308058.0 through Dec 2025, down 38.28% year-over-year, with the annual reading at $308058.0 for FY2025, 38.28% down from the prior year.
Gains from Sales and Divestitures for Q4 2025 was $308058.0 at Metagenomi, up from $250280.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $499148.0 in Q4 2024, with the low at $94413.0 in Q1 2025.